Focus: Lantheus is a public specialty biotech focused on small-molecule radiopharmaceuticals and imaging agents for oncology, cardiovascular, and metabolic disease detection. The company operates across nuclear medicine, PET, and ultrasound contrast modalities with a portfolio of legacy and emerging diagnostic agents.
Profile data last refreshed 12h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Lantheus Medical Imaging to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Legacy radiopharmaceutical with imminent loss of exclusivity; core revenue driver at risk.
Help build intelligence for Lantheus Medical Imaging
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Lantheus Medical Imaging's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Albumin-binding MRI contrast agent facing near-term generic competition.
Lead revenue asset with extended exclusivity through 2037; primary cash generator supporting pipeline.
Historical standard for cardiac stress testing; patent cliff near.
Pre-launch reformulation of legacy xenon product; modest catalyst potential.
Legacy diagnostic imaging agent with imminent patent expiration.
Flagship ultrasound contrast agent; same molecule as DEFINITY RT with extended runway.
6 discontinued, 1 duplicate formulations not shown
World Prefilled Radiopharmaceutical Vial - Market Analysis, Forecast, Size, Trends and Insights - IndexBox
World Prefilled Radiopharmaceutical Vial - Market Analysis, Forecast, Size, Trends and Insights IndexBox
Patent Claims On Novartis Unit Drug Invalid, Del. Judge Says - Law360
Patent Claims On Novartis Unit Drug Invalid, Del. Judge Says Law360
Radioligand Therapy (RLT) Market Size, Share | Global Industry 2035 - Market Research Future
Radioligand Therapy (RLT) Market Size, Share | Global Industry 2035 Market Research Future
Radiopharma Lantheus mulling $7B takeout offer from Curium: report - FirstWord Pharma
Radiopharma Lantheus mulling $7B takeout offer from Curium: report FirstWord Pharma
Radiopharmaceuticals Market Key Companies Analysis - General - openPR.com
Radiopharmaceuticals Market Key Companies Analysis - General openPR.com
World Medical Imaging Agent Producing System - Market Analysis, Forecast, Size, Trends and Insights - IndexBox
World Medical Imaging Agent Producing System - Market Analysis, Forecast, Size, Trends and Insights IndexBox
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo